Osteoporosis: ($7 billion) Oral Salmon Calcitonin
Phase IIa results presented at American Society of Bone and Mineral Research (ASBMR) Annual Meeting on 9/21/03 by Novartis
- Anti-resorptive activity of oral calcitonin confirmed by reduction of bone resorption markers
- No significant changes of bone formation markers observed throughout study period
- Consistent dose response demonstrated
- No serious adverse events
- This was the longest clinical study dosing period for oral calcitonin with the new oral delivery system